Trademark: 90528992
Word
COMPLETE360
Status
Pending
Status Code
733
Status Date
Thursday, December 14, 2023
Serial Number
90528992
Mark Type
4000
Filing Date
Monday, February 15, 2021
Published for Opposition
Tuesday, October 19, 2021

Trademark Owner History
COMPLETE OMICS INTERNATIONAL INC. - 1st New Owner After Publication
Complete Omics Inc. - Owner At Publication

Classifications
5 Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, human cancers, particularly, lymphomas, colorectal cancer, appendix cancer, uterine cancer, thyroid cancer, kidney cancer, lung cancer, breast cancer, ovarian cancer, pancreatic; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, chronic diseases, particularly, cardiovascular diseases, diabetes early detection, chronic kidney diseases; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, acute disease, particularly, sudden death prediction; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes; Diagnostic radiopharmaceutical agent for use in PET imaging; Diagnostic reagents and contrast media for medical use; Diagnostic reagents for medicinal use; Diagnostic test patch for application to the skin for determining allergies; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Medical diagnostic test strips for use in the field of human cancers, particularly, lymphomas, colorectal cancer, appendix cancer, uterine cancer, thyroid cancer, kidney cancer, lung cancer, breast cancer, ovarian cancer, pancreatic; Medical diagnostic test strips for use in the field of chronic diseases, particularly, cardiovascular diseases, diabetes early detection, chronic kidney diseases; Medical diagnostic test strips for use in the field of acute disease, particularly, sudden death prediction; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use
1 Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific or research use other than for medical use; Diagnostic preparations for scientific use; Diagnostic preparations other than for medical or veterinary purposes; Diagnostic preparations used in science; Diagnostic preparations, other than for medical or veterinary purposes; Diagnostic reagents and preparations, except for medical or veterinary use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use
44 Healthcare; Healthcare and medical tourism services, namely, establishing and maintaining a healthcare provider network in other countries for the provision of healthcare services; Healthcare services, namely, integrated healthcare services with a network of international healthcare providers; Consulting services in the field of healthcare; Consulting services in the fields of diagnostic medical testing and nutrition; Genetic testing of animals for diagnostic or treatment purposes; Health assessment services, namely, providing a database in the field of sleep apnea and home sleep testing diagnostic information based on collected data and information all for treatment and diagnostic purposes; Medical diagnostic testing, monitoring and reporting services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of human cancers, particularly, lymphomas, colorectal cancer, appendix cancer, uterine cancer, thyroid cancer, kidney cancer, lung cancer, breast cancer, ovarian cancer, pancreatic; Medical testing for diagnostic or treatment purposes in the field of chronic diseases, particularly, cardiovascular diseases, diabetes early detection, chronic kidney diseases; Medical testing for diagnostic or treatment purposes in the field of acute disease, particularly, sudden death prediction; Mobile healthcare services; Mobile healthcare services in the field of molecular diagnostics; Mobile healthcare services in the field of health surveillance; Providing healthcare information; Providing educational information about healthcare; Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing personalized healthcare and medical information in the nature of molecular diagnostics; Providing personalized healthcare and medical information in the nature of health surveillance; Psychological services, namely, providing diagnostic services to children with special needs and their families; Veterinary specialty services providing advanced medical, diagnostic or surgical services for animals; Veterinary testing for diagnostic or treatment purposes; Web-based cardiovascular analysis services for medical diagnostic and treatment purposes; Web-based cardiovascular examination and assessment for medical diagnostic purposes
10 Diagnostic apparatus for the detection of cancer; Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Medical diagnostic apparatus for analyzing and measuring electrolytes in the body; Medical diagnostic apparatus for detecting cancer; Medical diagnostic apparatus for testing DNA and RNA samples; Medical diagnostic apparatus for testing for viruses; Medical diagnostic instruments for the analysis of body fluids; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; Medical apparatus and instruments for diagnostic radiopharmaceutical use; Orthopedic apparatus and instruments for diagnostic and therapeutic use; Sample preparation device for medical diagnostic uses
COMPLETE THREE HUNDRED SIXTY; COMPLETE THREE SIX ZERO

Trademark Events
Dec 16, 2023
Notice Of Approval Of Extension Request E-Mailed
Dec 14, 2023
Sou Extension 4 Granted
Dec 14, 2023
Sou Extension 4 Filed
Dec 14, 2023
Sou Teas Extension Received
Jun 15, 2023
Notice Of Approval Of Extension Request E-Mailed
Jun 13, 2023
Sou Extension 3 Granted
Jun 13, 2023
Sou Extension 3 Filed
Jun 13, 2023
Sou Teas Extension Received
May 3, 2023
Automatic Update Of Assignment Of Ownership
Dec 7, 2022
Notice Of Approval Of Extension Request E-Mailed
Dec 5, 2022
Sou Extension 2 Granted
Dec 5, 2022
Sou Extension 2 Filed
Dec 5, 2022
Sou Teas Extension Received
Jun 15, 2022
Notice Of Approval Of Extension Request E-Mailed
Jun 13, 2022
Sou Extension 1 Granted
Jun 13, 2022
Sou Extension 1 Filed
Jun 13, 2022
Sou Teas Extension Received
Jun 10, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 10, 2022
Teas Change Of Correspondence Received
Jun 10, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 10, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 10, 2022
Teas Change Of Owner Address Received
Dec 14, 2021
Noa E-Mailed - Sou Required From Applicant
Oct 19, 2021
Official Gazette Publication Confirmation E-Mailed
Oct 19, 2021
Published For Opposition
Sep 29, 2021
Notification Of Notice Of Publication E-Mailed
Sep 15, 2021
Approved For Pub - Principal Register
Sep 15, 2021
Examiner's Amendment Entered
Sep 15, 2021
Notification Of Examiners Amendment E-Mailed
Sep 15, 2021
Examiners Amendment E-Mailed
Sep 15, 2021
Examiners Amendment -Written
Sep 10, 2021
Assigned To Examiner
May 18, 2021
New Application Office Supplied Data Entered
Feb 18, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24